Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)Ghayas C. Issa, Hagop M. Kantarjian, Courtney D. DiNardo et al.|Blood|2023Cited by 46